FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to T cells expressing a chimeric antigen receptor binding to a tumor cell antigen; it can be used in medicine. T cells can be used in a method for the treatment of a patient, in which malignant tumor of central nervous system is diagnosed, including intraventricular introduction of T cells, which provides for the effective immunotherapy of CNS tumor.
EFFECT: obtaining T cells for the cancer therapy.
17 cl, 42 dwg, 11 tbl, 24 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| CENTRAL MEMORY T-CELLS FOR ADOPTIVE T-CELL THERAPY | 2015 |
|
RU2763523C2 |
| CHIMERIC ANTIGEN RECEPTORS AIMED AT PSCA | 2016 |
|
RU2759879C2 |
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
| T-CELLS MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING CS1 | 2015 |
|
RU2727451C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2770002C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B CELLS, AND THEIR APPLICATION | 2015 |
|
RU2761632C2 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
